SynthesisBMC ophthalmology2025
Ocular manifestations of primary thrombotic microangiopathies : a descriptive systematic review.
Synthesis in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary thrombotic microangiopathies (TMAs) include Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS), which may cause ocular signs that need to be detected and managed accordingly. Therefore, we aim to identify the ocular manifestations caused by the systemic effects of primary TMAs, including HUS and TTP.
methodsWe searched PubMed, Scopus, and Web of Science databases from inception until March 2024. We included case reports, case series, and retrospective reviews reporting ocular manifestations of primary HUS or TTP. We excluded experimental studies, papers written in a language other than English, studies that included patients with secondary TTP or HUS, pregnant patients, patients with ocular trauma or surgery, and patients with other comorbidities that impair the detection of ocular findings.
resultsWe included 37 studies comprising 58 patients (mean age 18.87 ± 12.4 years), with a mean age of 18.87 years. The most common ocular manifestations were retinal hemorrhages (25.86%, n = 15), Purtscher-like retinopathy (24.13%, n = 14), retinal detachment (20.68%, n = 12), optic disc changes (18.96%, n = 11), capillary non-perfusion on fundus fluorescein angiography (FFA) (13.79%, n = 8), and isolated cotton-wool spots (12.06%, n = 7). Rarer manifestations were capillary leakage on FFA (n = 5, 8.6%), vascular tortuosity (8.6%, n = 5), retinal ischemic changes (8.6%, n = 5), sluggish pupil reactivity (6.9%, n = 4), vitreous hemorrhage (6.9%, n = 4), early hypofluorescence (6.9%, n = 4), hypopigmented subretinal lesions (6.9%, n = 4), shifting subretinal fluids (5.2%, n = 3), and attenuated retinal arterioles (5.2%, n = 3).
conclusionWe found that retinal hemorrhage, Purtscher-like retinopathy, retinal detachment, optic disc changes, capillary non-perfusion on FFA, and isolated cotton-wool spots were the most commonly reported ocular manifestations of primary TMAs. Identification of these manifestations will help to adequately detect and manage them in patients with primary TMAs. We recommend further investigations that provide reliable methods of prevention of those sequelae in patients with primary TMAs. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.